I. Introduction
Shingles, or herpes zoster, is a viral illness caused by reactivation of the varicella-zoster virus (VZV), which also causes chickenpox. After an initial chickenpox infection, the virus stays latent in nerve tissue and can reactivate later in life, resulting in shingles. The illness is distinguished by a severe, blistering rash that is frequently accompanied by burning or tingling feelings. Complications may include postherpetic neuralgia (PHN), visual impairment, and neurological difficulties.
The worldwide shingles market is expanding due to aging populations, increased knowledge of the illness, and improved access to preventative vaccinations and antiviral therapies. Shingrix, Zostavax, and SkyZoster vaccinations are available on the market, as are antiviral drugs such as acyclovir, valacyclovir, and famciclovir, as well as newer choices such as Amenamevir. The worldwide herpes zoster market is projected to rise at a CAGR of over 8% over the next decade, owing to increased healthcare spending and improved immunization programs (Databridge, 2022).
II. Factors Driving Market Growth
a. Rising Incidence of Shingles
The key driver of the shingles market is the disease's rising prevalence, particularly among older adults and immunocompromised patients. According to data from the United States, one in every three people will have shingles at some point in their lives, and the risk increases with age. Diseases that weaken the immune system such as diabetes, cancer, and HIV/AIDS, as well as immunosuppressive medications such as chemotherapy, make people more susceptible to the virus (US CDC, 2024).
b. Growing Awareness and Preventive Measures
Health agencies like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have conducted awareness efforts to increase public understanding of shingles and its implications. Many countries are introducing herpes zoster vaccination programs into national immunization schedules, resulting in increased vaccine uptake.
c. Advancements in Vaccination Technology
The development of recombinant vaccines, such as Shingrix, has greatly altered the shingles business. GlaxoSmithKline (GSK) developed Shingrix, which has showed over 90% effectiveness in preventing shingles and PHN. Unlike its predecessor, Zostavax, which is a live attenuated vaccine, Shingrix is an adjuvanted recombinant vaccine, making it safer and more effective, especially for immunocompromised people (GSK, 2022).
d. New Drug Mechanisms
Helicase-primase complex inhibitor, has the potential to reduce viral replication more efficiently than traditional nucleoside analogs. The approval and expansion of novel medicines such as Amenamevir are projected to boost market growth (Maruho, 2017).
e. Increasing Healthcare Expenditure and Access to Treatment
Increased healthcare spending globally improves availability to vaccinations and antiviral drugs. Governments and commercial healthcare providers are investing in immunization programs, pharmaceutical research, and public health activities to lower the prevalence of shingles and associated consequences. Emerging nations, notably those in Asia-Pacific and Latin America, are seeing a growth in the use of shingles treatments, such as the new live-attenuated vaccine SkyZoster, as healthcare infrastructure and insurance coverage improves (GVR, n.d.).
III. Market Segmentation
a. By Product Type
Vaccines: Shingrix, Zostavax, SkyZoster, and other pipeline vaccines.
Antiviral Medications: Acyclovir, Valacyclovir, Famciclovir, Amenamevir.
Pain Management Drugs: NSAIDs, corticosteroids, anticonvulsants (e.g., gabapentin, pregabalin), and opioid analgesics for PHN.
b. By Age Group
50–...
(All Rights Reserved)